Purine Nucleoside Phosphorylase Deficiency: Altered Kinetic Properties of a Mutant Enzyme
Irving H. Fox(Takeda (United States)), Douglas Biggar(Hospital for Sick Children), Catherine M. Andres(University of Michigan), Erwin W. Gelfand(National Jewish Health)
Cited by 55
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694